WO2005104648A3 - Nanopartículas pegiladas - Google Patents
Nanopartículas pegiladas Download PDFInfo
- Publication number
- WO2005104648A3 WO2005104648A3 PCT/ES2005/000226 ES2005000226W WO2005104648A3 WO 2005104648 A3 WO2005104648 A3 WO 2005104648A3 ES 2005000226 W ES2005000226 W ES 2005000226W WO 2005104648 A3 WO2005104648 A3 WO 2005104648A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nanoparticles
- polyethylene glycol
- type
- pegylation
- pvm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
- C08F222/04—Anhydrides, e.g. cyclic anhydrides
- C08F222/06—Maleic anhydride
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005237270A AU2005237270B2 (en) | 2004-04-29 | 2005-04-28 | Pegylated nanoparticles |
EP05745586A EP1752142B1 (en) | 2004-04-29 | 2005-04-28 | Pegylated nanoparticles |
US11/568,454 US8628801B2 (en) | 2004-04-29 | 2005-04-28 | Pegylated nanoparticles |
AT05745586T ATE442841T1 (de) | 2004-04-29 | 2005-04-28 | Pegylierte nanoteilchen |
DE602005016674T DE602005016674D1 (de) | 2004-04-29 | 2005-04-28 | Pegylierte nanoteilchen |
JP2007510054A JP2007534729A (ja) | 2004-04-29 | 2005-04-28 | ペグ化ナノ粒子 |
CA2564982A CA2564982C (en) | 2004-04-29 | 2005-04-28 | Pegylated nanoparticles |
BRPI0509827A BRPI0509827B8 (pt) | 2004-04-29 | 2005-04-28 | nanopartículas pegiladas para transporte de moléculas biologicamente ativas, composição farmacêutica, liofilizato constituindo nanopartículas pegiladas e processo de preparação de nanopartículas pegiladas |
MXPA06012583A MXPA06012583A (es) | 2004-04-29 | 2005-04-28 | Nanoparticulas pegiladas. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200401022A ES2246694B1 (es) | 2004-04-29 | 2004-04-29 | Nanoparticulas pegiladas. |
ESP200401022 | 2004-04-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005104648A2 WO2005104648A2 (es) | 2005-11-10 |
WO2005104648A3 true WO2005104648A3 (es) | 2005-12-08 |
Family
ID=35242088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2005/000226 WO2005104648A2 (es) | 2004-04-29 | 2005-04-28 | Nanopartículas pegiladas |
Country Status (13)
Country | Link |
---|---|
US (1) | US8628801B2 (es) |
EP (1) | EP1752142B1 (es) |
JP (1) | JP2007534729A (es) |
CN (1) | CN1976688A (es) |
AT (1) | ATE442841T1 (es) |
AU (1) | AU2005237270B2 (es) |
BR (1) | BRPI0509827B8 (es) |
CA (1) | CA2564982C (es) |
DE (1) | DE602005016674D1 (es) |
ES (2) | ES2246694B1 (es) |
MX (1) | MXPA06012583A (es) |
RU (1) | RU2400215C2 (es) |
WO (1) | WO2005104648A2 (es) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005072710A2 (en) | 2004-01-28 | 2005-08-11 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
DE602007012559D1 (de) * | 2006-09-08 | 2011-03-31 | Univ Johns Hopkins | H die schleimhaut |
ES2310122B1 (es) | 2007-04-20 | 2009-10-30 | Instituto Cientifico Y Tecnologico De Navarra, S.A | Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones. |
PL2197429T3 (pl) | 2007-09-03 | 2016-09-30 | Kompozycje w postaci cząstek do dostarczania słabo rozpuszczalnych leków | |
ES2358493B1 (es) * | 2008-04-05 | 2012-06-13 | Instituto Cientifico Y Tecnologico De Navarra, S.A | Nanopartículas pegiladas que comprenden una molécula biológicamente activa y sus aplicaciones. |
EP2538929A4 (en) * | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT |
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
ES2737960T3 (es) | 2010-10-01 | 2020-01-17 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos |
WO2012059936A1 (en) | 2010-11-03 | 2012-05-10 | Padma Venkitachalam Devarajan | Pharmaceutical compositions for colloidal drug delivery |
WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
EP2510930A1 (en) | 2011-04-15 | 2012-10-17 | Bionanoplus, S.L. | Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
RU2598627C2 (ru) | 2012-01-19 | 2016-09-27 | Дзе Джонс Хопкинс Юниверсити | Композиции на основе наночастиц с улучшенным проникновением через слизистые оболочки |
EA032552B1 (ru) | 2012-03-16 | 2019-06-28 | Дзе Джонс Хопкинс Юниверсити | Препараты с контролируемым высвобождением для доставки ингибиторов hif-1 |
EA030318B1 (ru) | 2012-03-16 | 2018-07-31 | Дзе Джонс Хопкинс Юниверсити | Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
JP6360040B2 (ja) | 2012-05-03 | 2018-07-18 | カラ ファーマシューティカルズ インコーポレイテッド | 粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法 |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
EP4008355A1 (en) | 2012-05-03 | 2022-06-08 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
AU2013256008B2 (en) | 2012-05-04 | 2016-02-25 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
WO2014124006A1 (en) | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
WO2014127214A1 (en) | 2013-02-15 | 2014-08-21 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
AU2014219024B2 (en) | 2013-02-20 | 2018-04-05 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
CN103483576B (zh) * | 2013-08-16 | 2015-04-08 | 辽宁鑫隆科技有限公司 | 一种蔗糖改性聚乙二醇醚的生产方法 |
KR102307175B1 (ko) | 2013-09-16 | 2021-10-01 | 아스트라제네카 아베 | 치료용 중합체 나노입자 및 이의 제조 방법과 사용 방법 |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2014342042B2 (en) | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
WO2015127389A1 (en) | 2014-02-23 | 2015-08-27 | The Johns Hopkins University | Hypotonic enema formulations and methods of use |
WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
BR112016024644A2 (pt) | 2014-04-23 | 2017-10-10 | Modernatx Inc | vacinas de ácido nucleico |
DK3233126T3 (en) * | 2014-12-01 | 2019-04-15 | Innoup Farma S L | NANOPARTICLES FOR ENCAPPING COMPOUNDS, MANUFACTURING AND APPLICATIONS THEREOF |
RU2729731C2 (ru) | 2014-12-15 | 2020-08-11 | Зе Джонс Хопкинс Юниверсити | Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний |
AU2016211696B2 (en) | 2015-01-27 | 2018-05-10 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
US10758520B1 (en) | 2015-05-20 | 2020-09-01 | University Of South Florida | Glutathione-coated nanoparticles for delivery of MKT-077 across the blood-brain barrier |
WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
SG11201803663XA (en) | 2015-11-12 | 2018-05-30 | Graybug Vision Inc | Aggregating microparticles for therapy |
WO2017106627A1 (en) | 2015-12-17 | 2017-06-22 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
WO2017177148A1 (en) | 2016-04-07 | 2017-10-12 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2018005552A1 (en) | 2016-06-27 | 2018-01-04 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
JP2019520379A (ja) | 2016-07-01 | 2019-07-18 | ジー1 セラピューティクス, インコーポレイテッド | ピリミジン系の抗増殖剤 |
BR112019004463A2 (pt) | 2016-09-08 | 2019-05-28 | Kala Pharmaceuticals Inc | formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso |
US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CA3036336A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
BR112019019452A2 (pt) | 2017-03-23 | 2020-04-14 | Graybug Vision Inc | composto, e, uso de um composto |
CN111201040A (zh) | 2017-05-10 | 2020-05-26 | 灰色视觉公司 | 用于医学疗法的缓释微粒及其悬浮液 |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
WO2019165134A1 (en) * | 2018-02-21 | 2019-08-29 | Texas Tech University System | Particles for targeted delivery of active agents into adipose stromal cells |
KR20210018199A (ko) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
WO2020041301A1 (en) | 2018-08-20 | 2020-02-27 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
EP3866773A4 (en) | 2018-10-16 | 2022-10-26 | Georgia State University Research Foundation, Inc. | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL CONDITIONS |
US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
WO2022006269A1 (en) * | 2020-06-30 | 2022-01-06 | The Johns Hopkins University | Non-intuitive combination of drug delivery carriers of the same drug for synergistic growth delay of solid tumors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6322817B1 (en) * | 1999-02-17 | 2001-11-27 | Dabur Research Foundation | Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof |
US6660810B1 (en) * | 1998-04-28 | 2003-12-09 | Debio Recherche Pharmaceutique Sa | Non cross-linked block polyetherester, preparation and uses |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4582865A (en) | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
GB8601100D0 (en) | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
FR2608988B1 (fr) | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
GB8723846D0 (en) | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
SE8900422D0 (sv) | 1989-02-08 | 1989-02-08 | Pharmacia Ab | Tvaerbundna hyaluronatgeler samt foerfarande foer framstaellning av dessa |
TW209174B (es) * | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
IT1247472B (it) | 1991-05-31 | 1994-12-17 | Fidia Spa | Processo per la preparazione di microsfere contenenti componenti biologicamente attivi. |
EP0544259A1 (en) | 1991-11-27 | 1993-06-02 | Lignyte Co., Ltd. | Water insoluble biocompatible hyaluronic and polyion complex and method of making the same |
US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US20010053359A1 (en) | 1994-07-26 | 2001-12-20 | Peter Watts | Drug delivery composition for the nasal administration of antiviral agents |
JPH10504828A (ja) | 1994-08-30 | 1998-05-12 | ハイアル ファーマスティカル コーポレイション | 細胞活性調整のためのヒアルロン酸およびその誘導体 |
ATE252894T1 (de) | 1995-01-05 | 2003-11-15 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
ES2098188B1 (es) | 1995-05-11 | 1997-12-16 | Univ Santiago Compostela | Desarrollo de nanoparticulas a base de polimeros hidrofilicos. |
ES2177592T3 (es) | 1995-07-05 | 2002-12-16 | Europ Economic Community | Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos. |
WO1997004747A1 (en) | 1995-07-27 | 1997-02-13 | Dunn James M | Drug delivery systems for macromolecular drugs |
US7276251B2 (en) | 1997-04-01 | 2007-10-02 | Lg Life Sciences, Ltd., Inc. | Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid |
ES2114502B1 (es) | 1996-07-29 | 1999-07-01 | Univ Santiago Compostela | Aplicacion de nanoparticulas a base de polimeros hidrofilicos como formas farmaceuticas. |
AU9799198A (en) | 1997-10-09 | 1999-05-03 | Vanderbilt University | Micro-particulate and nano-particulate polymeric delivery system |
DE19810965A1 (de) | 1998-03-13 | 1999-09-16 | Aventis Res & Tech Gmbh & Co | Nanopartikel, Verfahren zu ihrer Herstellung und ihre Verwendung |
FR2777193B1 (fr) | 1998-04-14 | 2001-06-08 | Coletica | Particule a groupement hydroxamique chelatante d'ions metalliques et leur utilisation en cosmetique ou en pharmacie |
JPH11302199A (ja) * | 1998-04-16 | 1999-11-02 | Sankyo Co Ltd | 薬物運搬体を構成するグラフト共重合体 |
US20030059465A1 (en) | 1998-05-11 | 2003-03-27 | Unger Evan C. | Stabilized nanoparticle formulations of camptotheca derivatives |
WO2000064954A1 (en) | 1999-04-22 | 2000-11-02 | Vanderbilt University | Polymeric encapsulation system promoting angiogenesis |
EP1194128A2 (en) | 1999-06-23 | 2002-04-10 | Sedum Laboratories | Ionically formulated biomolecule microcarriers |
AU774427B2 (en) | 1999-10-15 | 2004-06-24 | Fidia Advanced Biopolymers S.R.L. | Formulations of hyaluronic acid for delivery of osteogenic proteins |
US6743446B2 (en) | 1999-12-15 | 2004-06-01 | The Ohio State University Research Foundation | Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
EP1187602A4 (en) | 2000-04-18 | 2004-09-15 | Peptron Inc | SUSTAINABLE RELEASE INJECTABLE PHARMACEUTICAL COMPOSITION AND METHODS OF PREPARING THE SAME |
AU2001262596A1 (en) | 2000-05-03 | 2001-11-12 | Natural As | Compositions containing aminopolysaccharides and negatively charged polysaccharides |
KR100375299B1 (ko) | 2000-10-10 | 2003-03-10 | 주식회사 엘지생명과학 | 히알루론산의 가교결합형 아마이드 유도체와 이의 제조방법 |
ES2382636T3 (es) * | 2000-10-31 | 2012-06-12 | Surmodics Pharmaceuticals, Inc. | Método para producir composiciones para la administración mejorada de moléculas bioactivas |
ES2178961B1 (es) | 2001-03-06 | 2004-07-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas. |
ES2221530B1 (es) | 2002-07-19 | 2006-02-16 | Universidad De Santiago De Compostela | Nanoparticulas para la administracion de ingredientes activos,procedimiento para la elaboracion de dichas particulas y composicion que las contienen. |
RS20060077A (en) | 2003-08-12 | 2008-08-07 | Octapharma Ag., | Process for preparing an alpha-1-antitrypsin solution |
ES2246695B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico. |
-
2004
- 2004-04-29 ES ES200401022A patent/ES2246694B1/es not_active Expired - Fee Related
-
2005
- 2005-04-28 AT AT05745586T patent/ATE442841T1/de not_active IP Right Cessation
- 2005-04-28 US US11/568,454 patent/US8628801B2/en active Active
- 2005-04-28 DE DE602005016674T patent/DE602005016674D1/de active Active
- 2005-04-28 AU AU2005237270A patent/AU2005237270B2/en active Active
- 2005-04-28 RU RU2006142100/15A patent/RU2400215C2/ru active
- 2005-04-28 WO PCT/ES2005/000226 patent/WO2005104648A2/es active Application Filing
- 2005-04-28 EP EP05745586A patent/EP1752142B1/en active Active
- 2005-04-28 BR BRPI0509827A patent/BRPI0509827B8/pt active IP Right Grant
- 2005-04-28 JP JP2007510054A patent/JP2007534729A/ja active Pending
- 2005-04-28 ES ES05745586T patent/ES2333659T3/es active Active
- 2005-04-28 CA CA2564982A patent/CA2564982C/en active Active
- 2005-04-28 MX MXPA06012583A patent/MXPA06012583A/es active IP Right Grant
- 2005-04-28 CN CNA2005800218392A patent/CN1976688A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6660810B1 (en) * | 1998-04-28 | 2003-12-09 | Debio Recherche Pharmaceutique Sa | Non cross-linked block polyetherester, preparation and uses |
US6322817B1 (en) * | 1999-02-17 | 2001-11-27 | Dabur Research Foundation | Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof |
Non-Patent Citations (2)
Title |
---|
CHIELLINI E ET AL: "Design of polymeric systems for targeted administration of peptide and protein drugs.", POLYMER PREPRINTS., vol. 39, no. 2, 1998, pages 182 - 183, XP008074021 * |
YONCHEVA K ET AL: "Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties.", EUROPEAN J OF PHARMACEUTICAL SCIENCE., vol. 24, no. 5, April 2005 (2005-04-01), pages 411 - 419, XP004793979 * |
Also Published As
Publication number | Publication date |
---|---|
US8628801B2 (en) | 2014-01-14 |
ES2333659T3 (es) | 2010-02-25 |
ES2246694B1 (es) | 2007-05-01 |
BRPI0509827B1 (pt) | 2020-11-03 |
EP1752142A2 (en) | 2007-02-14 |
ES2246694A1 (es) | 2006-02-16 |
BRPI0509827B8 (pt) | 2021-05-25 |
EP1752142B1 (en) | 2009-09-16 |
DE602005016674D1 (de) | 2009-10-29 |
RU2006142100A (ru) | 2008-06-20 |
CA2564982A1 (en) | 2005-11-10 |
AU2005237270B2 (en) | 2011-02-17 |
MXPA06012583A (es) | 2007-03-21 |
BRPI0509827A (pt) | 2007-10-23 |
WO2005104648A2 (es) | 2005-11-10 |
CN1976688A (zh) | 2007-06-06 |
ATE442841T1 (de) | 2009-10-15 |
JP2007534729A (ja) | 2007-11-29 |
US20080248125A1 (en) | 2008-10-09 |
RU2400215C2 (ru) | 2010-09-27 |
AU2005237270A1 (en) | 2005-11-10 |
CA2564982C (en) | 2015-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005104648A3 (es) | Nanopartículas pegiladas | |
Deng et al. | Disulfide‐based self‐Immolative linkers and functional bioconjugates for biological applications | |
Riber et al. | Self‐Immolative linkers literally bridge disulfide chemistry and the realm of Thiol‐free drugs | |
Gupta et al. | Dendrimers: novel polymeric nanoarchitectures for solubility enhancement | |
Kurtoglu et al. | Drug release characteristics of PAMAM dendrimer–drug conjugates with different linkers | |
Li et al. | Acetal-linked polymeric prodrug micelles for enhanced curcumin delivery | |
GEP20115200B (en) | Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same | |
WO2005048952A3 (en) | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle | |
CN105727309A (zh) | 双敏感两亲性多糖-阿霉素偶联物及其药学组合物的制备和应用 | |
ATE360659T1 (de) | Synthese von nicht-peptidischen polymerderivaten mit hohem molekulargewicht | |
CA2409828A1 (en) | Formulation based in heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base | |
Silva et al. | Dendrimers as potential platform in nanotechnology-based drug delivery systems | |
Andersson et al. | Poly (ethylene glycol)-poly (ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates | |
Wei et al. | Thermosensitive β-cyclodextrin modified poly (ε-caprolactone)-poly (ethylene glycol)-poly (ε-caprolactone) micelles prolong the anti-inflammatory effect of indomethacin following local injection | |
Tawfik et al. | Polyamidoamine (PAMAM) dendrimers as potential release modulators and oral bioavailability enhancers of vardenafil hydrochloride | |
WO2009070380A3 (en) | Water-soluble carbon nanotube compositions for drug delivery and medical applications | |
Ci et al. | Simply mixing with poly (ethylene glycol) enhances the fraction of the active chemical form of antitumor drugs of camptothecin family | |
Li et al. | Drug-induced hierarchical self-assembly of poly (amino acid) for efficient intracellular drug delivery | |
Han et al. | Mechanochemical drug conjugation via ph-responsive imine linkage for polyether prodrug micelles | |
WO2006034147A3 (en) | Compositions and methods for the preparation and administration of poorly water soluble drugs | |
Li et al. | Cyclodextrin-Based Polymeric Drug Delivery Systems for Cancer Therapy | |
Dong et al. | Amphiphilic triblock copolymer prodrug for tumor-specific pH/reduction dual-triggered drug delivery: effect of self-assembly behaviors | |
DE60119905D1 (de) | Verfahren zur herstellung fester dispersionen | |
Jin et al. | Enhanced oral bioavailability of 10-hydroxycamptothecin through the use of poly (n-butyl cyanoacrylate) nanospheres | |
Sun et al. | Polymer-based prodrugs for cancer chemotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2564982 Country of ref document: CA Ref document number: PA/a/2006/012583 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007510054 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005237270 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005745586 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006142100 Country of ref document: RU Ref document number: 4390/CHENP/2006 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2005237270 Country of ref document: AU Date of ref document: 20050428 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005237270 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11568454 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580021839.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2005745586 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0509827 Country of ref document: BR |